Sliding scale insulin
Phase 2Small molecule
Sliding scale insulin is one of 18 small molecule programs targeting Diabetes Mellitus, Type 2. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Diabetes Mellitus, Type 2
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Mounjaro
Eli LillyApproved
Farxiga
AstraZenecaApproved
Trulicity
Eli LillyApproved
Actos
TakedaApproved
Jardiance
Boehringer IngelheimApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Glucophage
EMD SeronoApproved
Invokana
WWim Janssens
Approved
Tradjenta
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sliding scale insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSlotervaart Hospital